{"id":"W3171517418","doi":"10.1016/s0140-6736(21)00797-2","title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2927,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Gastric adenocarcinoma; Gastro-; Chemotherapy; Nivolumab; Internal medicine; Gastroenterology; Open label; Adenocarcinoma; Gastroesophageal Junction; Oncology; Clinical trial; Cancer; Reflux; Immunotherapy; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}